What is Gilteritinib?

Gilteritinib (Gilteritinib) is mainly used in the treatment of FLT3 gene mutation subtypes in patients with acute myeloid leukemia (Acute Myeloid Leukemia, AML).

AMLIt is a hematological malignancy that involves abnormal proliferation and poorly matured leukemia cells in the bone marrow. FLT3 (FMS-Like Tyrosine Kinase 3) gene mutations are relatively common in AML patients, accounting for about 30% of cases. This mutation leads to abnormal activation of FLT3 receptor tyrosine kinase, which in turn stimulates the growth and differentiation of leukemia cells and worsens the condition of AML.

The mechanism of action of giritinib is to prevent the uncontrolled proliferation of leukemia cells by inhibiting the activity of FLT3 receptor tyrosine kinase. This highly selective targeted therapy makes giritinib an effective tool for the treatment of patients with AML harboring mutations in the FLT3 gene.

Giritinib has achieved remarkable efficacy in clinical trials, especially in AML patients, including newly diagnosed AML patients and relapsed /refractory AML patients. It is widely studied to increase survival rates and improve the quality of life of AML patients.

It should be noted that gilitinib is not suitable for allAML patients, but is mainly used for patients with FLT3Subtypes of genetic mutations. Treatment with giritinib should be done under the supervision of a physician, with a treatment plan based on the patient's specific condition and medical guidance. Although giritinib may cause some side effects, it represents an important advance in the treatment of AML and provides a new treatment option to improve patient prognosis. Therefore, patients should actively work with their medical professionals to determine the most appropriate treatment options.

Giritinib is currently on the market in China, but it is not included in medical insurance. If patients need it, they can go to the hospital to buy it at their own expense, but the price is very high, about 35,000 yuan. For specific prices, please consult the local hospital pharmacy. Foreign original drugs of gilitinib are even more expensive. For example, the price of the Hong Kong version of the original drug is around 90,000 yuan, and the European version of the original drug is as high as more than 200,000 yuan, which is simply unaffordable for ordinary patients. There are already foreign generic drugs of Giritinib on the market, mainly Laos generic drugs. The price is about four to five thousand yuan, which is relatively cheap. In terms of drug ingredients, the ingredients of domestic and foreign original gilitinib drugs are basically the same as those of generic drugs.